PURPOSE: We investigated the retinal disease due to mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene in human patients and in an Rpgr conditional knockout (cko) mouse model. METHODS: XLRP patients with RPGR-ORF15 mutations (n = 35, ages at first visit 5-72 years) had clinical examinations, and rod and cone perimetry. Rpgr-cko mice, in which the proximal promoter and first exon were deleted ubiquitously, were back-crossed onto a BALB/c background, and studied with optical coherence tomography and electroretinography (ERG). Retinal histopathology was performed on a subset. RESULTS: Different patterns of rod and cone dysfunction were present in patients. Frequently, there were midperipheral losses with residual rod and cone function in central and peripheral retina. Longitudinal data indicated that central rod loss preceded peripheral rod losses. Central cone-only vision with no peripheral function was a late stage. Less commonly, patients had central rod and cone dysfunction, but preserved, albeit abnormal, midperipheral rod and cone vision. Rpgr-cko mice had progressive retinal degeneration detectable in the first months of life. ERGs indicated relatively equal rod and cone disease. At late stages, there was greater inferior versus superior retinal degeneration. CONCLUSIONS: RPGR mutations lead to progressive loss of rod and cone vision, but show different patterns of residual photoreceptor disease expression. Knowledge of the patterns should guide treatment strategies. Rpgr-cko mice had onset of degeneration at relatively young ages and progressive photoreceptor disease. The natural history in this model will permit preclinical proof-of-concept studies to be designed and such studies should advance progress toward human therapy.
PURPOSE: We investigated the retinal disease due to mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene in humanpatients and in an Rpgr conditional knockout (cko) mouse model. METHODS: XLRP patients with RPGR-ORF15 mutations (n = 35, ages at first visit 5-72 years) had clinical examinations, and rod and cone perimetry. Rpgr-cko mice, in which the proximal promoter and first exon were deleted ubiquitously, were back-crossed onto a BALB/c background, and studied with optical coherence tomography and electroretinography (ERG). Retinal histopathology was performed on a subset. RESULTS: Different patterns of rod and cone dysfunction were present in patients. Frequently, there were midperipheral losses with residual rod and cone function in central and peripheral retina. Longitudinal data indicated that central rod loss preceded peripheral rod losses. Central cone-only vision with no peripheral function was a late stage. Less commonly, patients had central rod and cone dysfunction, but preserved, albeit abnormal, midperipheral rod and cone vision. Rpgr-cko mice had progressive retinal degeneration detectable in the first months of life. ERGs indicated relatively equal rod and cone disease. At late stages, there was greater inferior versus superior retinal degeneration. CONCLUSIONS:RPGR mutations lead to progressive loss of rod and cone vision, but show different patterns of residual photoreceptor disease expression. Knowledge of the patterns should guide treatment strategies. Rpgr-cko mice had onset of degeneration at relatively young ages and progressive photoreceptor disease. The natural history in this model will permit preclinical proof-of-concept studies to be designed and such studies should advance progress toward human therapy.
Authors: Samuel G Jacobson; Artur V Cideciyan; Tomas S Aleman; Michael J Pianta; Alexander Sumaroka; Sharon B Schwartz; Elaine E Smilko; Ann H Milam; Val C Sheffield; Edwin M Stone Journal: Hum Mol Genet Date: 2003-05-01 Impact factor: 6.150
Authors: T S Aleman; M M LaVail; R Montemayor; G Ying; M M Maguire; A M Laties; S G Jacobson; A V Cideciyan Journal: Vision Res Date: 2001-09 Impact factor: 1.886
Authors: Tomas S Aleman; Artur V Cideciyan; Nicholas J Volpe; Giovanni Stevanin; Alexis Brice; Samuel G Jacobson Journal: Exp Eye Res Date: 2002-06 Impact factor: 3.467
Authors: Eliot L Berson; Bernard Rosner; Carol Weigel-DiFranco; Thaddeus P Dryja; Michael A Sandberg Journal: Invest Ophthalmol Vis Sci Date: 2002-09 Impact factor: 4.799
Authors: Xinhua Shu; Julie R Simpson; Alan W Hart; Zhihong Zeng; Sarita Rani Patnaik; Philippe Gautier; Emma Murdoch; Brian Tulloch; Alan F Wright Journal: Invest Ophthalmol Vis Sci Date: 2012-06-26 Impact factor: 4.799
Authors: Zhijian Wu; Suja Hiriyanna; Haohua Qian; Suddhasil Mookherjee; Maria M Campos; Chun Gao; Robert Fariss; Paul A Sieving; Tiansen Li; Peter Colosi; Anand Swaroop Journal: Hum Mol Genet Date: 2015-04-15 Impact factor: 6.150
Authors: William A Beltran; Artur V Cideciyan; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre Journal: Cold Spring Harb Perspect Med Date: 2014-10-09 Impact factor: 6.915
Authors: William A Beltran; Artur V Cideciyan; Simone Iwabe; Malgorzata Swider; Mychajlo S Kosyk; Kendra McDaid; Inna Martynyuk; Gui-Shuang Ying; James Shaffer; Wen-Tao Deng; Sanford L Boye; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre Journal: Proc Natl Acad Sci U S A Date: 2015-10-12 Impact factor: 11.205
Authors: Wen-Tao Deng; Frank M Dyka; Astra Dinculescu; Jie Li; Ping Zhu; Vince A Chiodo; Sanford L Boye; Thomas J Conlon; Kirsten Erger; Travis Cossette; William W Hauswirth Journal: Hum Gene Ther Date: 2015-07-29 Impact factor: 5.695
Authors: Alejandro J Roman; Artur V Cideciyan; Sharon B Schwartz; Melani B Olivares; Elise Heon; Samuel G Jacobson Journal: Invest Ophthalmol Vis Sci Date: 2013-02-15 Impact factor: 4.799
Authors: Sanford L Boye; Igor V Peshenko; Wei Chieh Huang; Seok Hong Min; Issam McDoom; Christine N Kay; Xuan Liu; Frank M Dyka; Thomas C Foster; Yumiko Umino; Sukanya Karan; Samuel G Jacobson; Wolfgang Baehr; Alexander Dizhoor; William W Hauswirth; Shannon E Boye Journal: Hum Gene Ther Date: 2013-02 Impact factor: 5.695
Authors: Samuel G Jacobson; Artur V Cideciyan; Wei Chieh Huang; Alexander Sumaroka; Alejandro J Roman; Sharon B Schwartz; Xunda Luo; Rebecca Sheplock; Joanna M Dauber; Malgorzata Swider; Edwin M Stone Journal: Invest Ophthalmol Vis Sci Date: 2014-07-29 Impact factor: 4.799